Literature DB >> 22722629

GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure.

Kathrin Brockmann1, Ruediger Hilker, Ulrich Pilatus, Simon Baudrexel, Karin Srulijes, Jörg Magerkurth, Ann-Kathrin Hauser, Claudia Schulte, Ilona Csoti, Caroline Denise Merten, Thomas Gasser, Daniela Berg, Elke Hattingen.   

Abstract

OBJECTIVE: To elucidate possible mechanisms leading to neurodegeneration in patients with glucocerebrosidase (GBA)-associated Parkinson disease (PD) using combined proton ((1)H) and phosphorus ((31)P) magnetic resonance spectroscopic imaging (MRSI) in vivo.
METHODS: (1)H and (1)H-decoupled (31)P MRSI was performed in 13 patients with PD with heterozygous GBA mutations (GBA-PD) and 19 age- and sex-matched healthy controls to investigate metabolite concentrations in the mesostriatal target regions of PD pathology. NAA as marker of neuronal integrity, choline and ethanolamine containing compounds as markers of membrane phospholipid metabolism, and energy metabolites (notably high-energy phosphates) were quantified.
RESULTS: Compared to controls, NAA was significantly reduced in the putamen (p = 0.012) and in the midbrain of GBA-PD (p = 0.05). The choline concentration obtained from (1)H MRSI was significantly decreased in the midbrain of GBA-PD (p = 0.010). The phospholipid degradation product glycerophosphoethalonamine was increased in the putamen of GBA-PD (p = 0.05). Changes of energy metabolism were not detected in any region of interest.
CONCLUSION: The pattern of neurodegeneration in GBA-associated PD is more pronounced in the putamen than in the midbrain. Our MRSI findings suggest that the neurodegenerative process in GBA-PD is associated with alterations of membrane phospholipid metabolism which might be also involved in abnormal α-synuclein aggregation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22722629     DOI: 10.1212/WNL.0b013e31825dd369

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy.

Authors:  Reena V Kartha; James Joers; Marcia R Terluk; Abigail Travis; Kyle Rudser; Paul J Tuite; Neal J Weinreb; Jeanine R Jarnes; James C Cloyd; Gülin Öz
Journal:  J Inherit Metab Dis       Date:  2019-12-17       Impact factor: 4.982

Review 2.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

Review 3.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

Review 4.  [Genetics of movement disorders].

Authors:  K Lohmann; K Brockmann
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

Review 5.  The association between ß-glucocerebrosidase mutations and parkinsonism.

Authors:  Matthew Swan; Rachel Saunders-Pullman
Journal:  Curr Neurol Neurosci Rep       Date:  2013-08       Impact factor: 5.081

Review 6.  The significance of GBA for Parkinson's disease.

Authors:  Kathrin Brockmann; Daniela Berg
Journal:  J Inherit Metab Dis       Date:  2014-06-04       Impact factor: 4.982

7.  Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death.

Authors:  Marcus Keatinge; Hai Bui; Aswin Menke; Yu-Chia Chen; Anna M Sokol; Qing Bai; Felix Ellett; Marc Da Costa; Derek Burke; Matthew Gegg; Lisa Trollope; Thomas Payne; Aimee McTighe; Heather Mortiboys; Sarah de Jager; Hugh Nuthall; Ming-Shang Kuo; Angeleen Fleming; Anthony H V Schapira; Stephen A Renshaw; J Robin Highley; Agnieszka Chacinska; Pertti Panula; Edward A Burton; Michael J O'Neill; Oliver Bandmann
Journal:  Hum Mol Genet       Date:  2015-09-16       Impact factor: 6.150

8.  No evidence for substrate accumulation in Parkinson brains with GBA mutations.

Authors:  Matthew E Gegg; Lindsay Sweet; Bing H Wang; Lamya S Shihabuddin; Sergio Pablo Sardi; Anthony H V Schapira
Journal:  Mov Disord       Date:  2015-06-11       Impact factor: 10.338

Review 9.  Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis.

Authors:  Peter Jenner; Huw R Morris; Trevor W Robbins; Michel Goedert; John Hardy; Yoav Ben-Shlomo; Paul Bolam; David Burn; John V Hindle; David Brooks
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

10.  Dynamic metabolic patterns tracking neurodegeneration and gliosis following 26S proteasome dysfunction in mouse forebrain neurons.

Authors:  Philippine C Geiszler; Aslihan Ugun-Klusek; Karen Lawler; Marie-Christine Pardon; Ding Yuchun; Li Bai; Clare A Daykin; Dorothee P Auer; Lynn Bedford
Journal:  Sci Rep       Date:  2018-03-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.